EMA grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for #AcuteRadiationSyndrome (ARS). This milestone underscores NT-I7’s potential to address the critical unmet medical need in ARS. Read more in the full press release prn.to/3VbPoQ6

Today we announce the filing of an international patent for our innovative multi-specific antibody platform technology, a significant step forward in our T-cell immunotherapy research.  This technology opens doors to innovative treatments. Read more here bit.ly/3VO9Mat

We’re sharing interim results from our Phase 1b study at #ESMO2024! NT-I7 combined with CAR-T therapy shows potential in enhancing CAR-T cell expansion and persistence, with a solid safety profile. A promising step forward for LBCL patients! 🔗 prn.to/4gjs5hi

We're pleased to share Q3 achievements! ✔️ Raised ₩12B convertible bonds 🔬 Phase 1b #clinicaltrial: 81.1% response in LBCL with NT-I7 + CAR-T ⭐️ Completed FDA Type C meeting for NT-I7 in ICL ➡️Read the full update 🔗bit.ly/4edA0KO #immunotherapy

NeoImmuneTech at #SITC24: Biomarker insights in GI cancers predict benefit from NT-I7 + Keytruda, and IL-7 enhances immune response in lung cancer. Learn more 👇 🔗 jitc.bmj.com/content/12/Sup…

At #IPVC24, NeoImmuneTech presents NT-I7 treatment for ICL & refractory HPV-related skin/mucosal disease, showing T-cell recovery. Potential for IL-7 as neo-adjuvant therapy. ➡️ You can find our abstract #1833 online at ipvconference.org

Don’t miss our oral presentation at #ASH24! 📅 7 Dec 2024 ⏰ 1:15pm PST 📍 San Diego Convention Center, Room 24 Discover how NT-I7 promotes T cell recovery post-radiation injury. Join us! #TCellTherapeutics

Promising results at #ASH24: NeoImmuneTech’s NT-I7 accelerates T cell recovery after radiation injury. Full details here: neoimmunetech.com/en/irpr/news/8…

3 key milestones for NT-I7 in Q4 2024! 🧪 Primate study underway for #acuteradiationsyndrome (ARS) 🩺 #ASH2024 NT-I7 aids T cell recovery after radiation 🧬 Frontiers in Immunology: NT-I7 boosts immuno-oncology outcomes in #lymphopenia. Read more 🔗 bit.ly/40jZa6F

We are attending #BioPartnering at JPM Week (January 13–16, 2025) in San Francisco. Our focus is NT‑I7, a long‑acting IL‑7 that may amplify T‑cell in immunotherapy. For more details or to schedule a meeting, please email Dr. Dan Rho at [email protected].

📢 #NeoImmuneTech @#AACR2025! NT-I7 restores lymphopenia & boosts anti-cancer efficacy in HNSCC models 🔬 💥Strong synergy with Cisplatin + anti-PD-1 💡NT-I7 expands CD8+ Tpex cells, suggesting combo therapy potential #CancerResearch #Immunotherapy 🔗bit.ly/3GXQrj6

네오이뮨텍이 #AACR2025 에서 두경부암 비임상 모델에서 림프구 회복과 항암 시너지를 입증한 결과를 발표했습니다. 🧪 시스플라틴, 면역관문억제제 병용 시 강력한 효과 💡 면역세포 분석 통해 Tpex 세포 확장 확인 #면역항암제 #CancerResearch #Immunotherapy 🔗bit.ly/3GGTM6e

Final results from NeoImmuneTech’s Ph1b trial of NT-I7 + CAR-T! 100% ORR in high-dose cohort and 88% maintained response >6mo🛡️ No CRS or ICANS after NT-I7 🧬 RP2D: 720 μg/kg 🤝 Partner talks ongoing — meet us at #BIO2025! 🔗bit.ly/4mnfYCA #CAR_T #NTI7 #Immunotherapy

네오이뮨텍, NT-I7+CAR-T 병용 임상 최종 결과 발표 💥고용량군 반응률 100% 및 6개월 이상 지속 88% 🛡️ NT-I7 투여 이후 CRS·ICANS 이상반응 ‘0건’ 🧬RP2D 720 μg/kg BIO 2025에서 글로벌 제약사와 후속 논의를 이어 나갈 예정입니다 🔗 bit.ly/43BMnxZ #네오이뮨텍 #CAR_T #NTI7 #면역항암

IND submitted to the FDA for a follow-up trial of #NTI7 + CAR-T! Led by Dr. John DiPersio, this IIT explores a repeated dosing strategy (Day 10 & 31) in #LBCL patients. 📄bit.ly/3IpyJGa #NeoImmuneTech #Immunotherapy #CART

NT-I7·CAR-T 병용 후속 임상, 美 FDA에 IND 제출! 워싱턴대 John DiPersio 박사 주도 연구자 임상에서#LBCL 환자 대상으로 NT-I7 10일·31일 반복 투여 전략을 통해 치료 반응을 극대화 하고자 합니다. 📄 bit.ly/46Hfe5Y #NeoImmuneTech #Immunotherapy #CART

🔬 FDA has cleared an IIT led by Drs. John DiPersio & Zachary D. Crees testing repeat dosing of NT-I7 (efineptakin alfa) post CAR-T in r/r LBCL. Two-dose strategy on Days 10 & 31 aims to boost CAR-T persistence & durability. 👉 bit.ly/46Slwjq#NTI7 #CART #Immunotherapy

🔬 美 FDA, CAR-T 병용 NT-I7 반복투여 연구자 주도 임상 승인 John DiPersio·Zachary D. Crees 박사 주도, 10일차·31일차 투여 전략으로 CAR-T 지속성·효과 향상 목표 👉 bit.ly/4fy1DAf #NTI7 #CART #임상시험 #면역항암제

🚀 NeoImmuneTech Announces IND for NT-I7 + BCMA CAR-T Trial WashU Med filed IND for Ph1 of NT-I7+BCMA CAR-T in multiple myeloma, led by Dr. Slade in collab with Dr. DiPersio, expanding NT-I7's CAR-T strategy 📷 bit.ly/3Jw6kyY #NeoImmuneTech #NTI7 #CART

🚀 네오이뮨텍, NT-I7 + BCMA CAR-T 병용 임상 美 FDA IND 제출 WashU Medicine이 다발성골수종(MM) 환자 대상 연구자주도임상 IND를 FDA에 제출 마이클 슬레이드 조교수 주도, 존 디퍼시오 교수 협력 NT-I7의 CAR-T 병용 전략 BCMA로 확장 📄 bit.ly/4388ED4 #NeoImmuneTech #NTI7 #CART